New research has shown that GLP‑1 weight-loss drugs deliver protection against heart attacks, strokes, and premature death over a sustained period of time. Researchers from Anglia Ruskin University (ARU) analyzed data from more than 90,000 patients enrolled in large-scale international studies and found that people given glucagon-like peptide‑1 (GLP‑1) receptor agonists were significantly less likely to suffer major cardiovascular events than those given a placebo.
Continue Reading this article here
